Status:
COMPLETED
Comparison of Generic and Original Formulation of Clopidogrel
Lead Sponsor:
University of Pecs
Collaborating Sponsors:
Hungarian Academy of Sciences
KRKA
Conditions:
Coronary Heart Disease
Percutaneous Coronary Intervention
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Clopidogrel is essential for the prevention of vascular events in patients after percutaneous coronary interventions (PCI). Most of our current knowledge with clopidogrel originates from the clinical ...
Detailed Description
Clopidogrel is essential for the prevention of vascular events in patients after percutaneous coronary interventions (PCI). Most of our current knowledge with clopidogrel originates from the clinical ...
Eligibility Criteria
Inclusion
- Patients in the maintenance phase of PCI receiving 1x75 mg clopidogrel and 1x100 mg aspirin
- No planned interruption of the antiplatelet therapy in the next 1 month
- Informed consent
Exclusion
- Oral anticoagulant therapy
- Contraindication for aspirin or clopidogrel
- Planned interruption of antiplatelet therapy in the next month
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT01147133
Start Date
November 1 2009
End Date
May 1 2010
Last Update
January 29 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.